Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 783

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 783
---
 | ​ | $                   |      — | ​ | $          |   — | ​ | $                    |  8,877 | ​ | $          |   -623 | ​ | $     |  8,877 | ​ | $          |   -623 |
| Corporate bonds                    | ​ |                     |  1,470 | ​ |            | -26 | ​ |                      | 33,715 | ​ |            |   -617 | ​ |       | 35,185 | ​ |            |   -643 |
| Commercial paper                   | ​ |                     | 15,906 | ​ |            |  -6 | ​ |                      |      — | ​ |            |      — | ​ |       | 15,906 | ​ |            |     -6 |
| Municipal bonds                    | ​ |                     |    982 | ​ |            | -16 | ​ |                      | 19,589 | ​ |            |   -386 | ​ |       | 20,571 | ​ |            |   -402 |
| Total                              | ​ | $                   | 18,358 | ​ | $          | -48 | ​ | $                    | 62,181 | ​ | $          | -1,626 | ​ | $     | 80,539 | ​ | $          | -1,674 |

As of December 31, 2023 and 2022, respectively,noallowance for credit losses were recognized on the Company’s available-for-sale debt securities asnoportion of the unrealized losses associated with those securities were due to credit losses. The information that the Company considered in reaching the conclusion that an allowance for credit losses was not necessary for the following categories of securities is as follows:

As of December 31, 2023 and 2022, the Company held a total of3out of9positions and35out of39positions, respectively, that were in an unrealized loss position, all of which had been in an unrealized loss position for 12 months or greater as of December 31, 2023. Unrealized losses individually and in aggregate, including any in an unrealized loss position for 12 months or greater, were not considered to be material for each respective period. Based on the Company’s review of these securities, the Company believes that the cost basis of its available-for-sale marketable securities is recoverable.

U.S. Treasury securities and U.S. government agency obligations.The unrealized losses on the